These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34213063)

  • 21. MT1-selective melatonin receptor ligands: synthesis, pharmacological evaluation, and molecular dynamics investigation of N-{[(3-O-substituted)anilino]alkyl}amides.
    Rivara S; Pala D; Lodola A; Mor M; Lucini V; Dugnani S; Scaglione F; Bedini A; Lucarini S; Tarzia G; Spadoni G
    ChemMedChem; 2012 Nov; 7(11):1954-64. PubMed ID: 22927210
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel conformationally constrained analogues of agomelatine as new melatoninergic ligands.
    Rami M; Landagaray E; Ettaoussi M; Boukhalfa K; Caignard DH; Delagrange P; Berthelot P; Yous S
    Molecules; 2012 Dec; 18(1):154-66. PubMed ID: 23262445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. XFEL structures of the human MT
    Johansson LC; Stauch B; McCorvy JD; Han GW; Patel N; Huang XP; Batyuk A; Gati C; Slocum ST; Li C; Grandner JM; Hao S; Olsen RHJ; Tribo AR; Zaare S; Zhu L; Zatsepin NA; Weierstall U; Yous S; Stevens RC; Liu W; Roth BL; Katritch V; Cherezov V
    Nature; 2019 May; 569(7755):289-292. PubMed ID: 31019305
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis and pharmacological evaluation of new series of naphthalenic analogues as melatoninergic (MT1/MT2) and serotoninergic 5-HT2C dual ligands (I).
    Ettaoussi M; Sabaouni A; Rami M; Boutin JA; Delagrange P; Renard P; Spedding M; Caignard DH; Berthelot P; Yous S
    Eur J Med Chem; 2012 Mar; 49():310-23. PubMed ID: 22301214
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Homology modeling of MT1 and MT2 receptors.
    Farce A; Chugunov AO; Logé C; Sabaouni A; Yous S; Dilly S; Renault N; Vergoten G; Efremov RG; Lesieur D; Chavatte P
    Eur J Med Chem; 2008 Sep; 43(9):1926-44. PubMed ID: 18255198
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Promotion of non-rapid eye movement sleep and activation of reticular thalamic neurons by a novel MT2 melatonin receptor ligand.
    Ochoa-Sanchez R; Comai S; Lacoste B; Bambico FR; Dominguez-Lopez S; Spadoni G; Rivara S; Bedini A; Angeloni D; Fraschini F; Mor M; Tarzia G; Descarries L; Gobbi G
    J Neurosci; 2011 Dec; 31(50):18439-52. PubMed ID: 22171046
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis of a novel series of tricyclic dihydrofuran derivatives: discovery of 8,9-dihydrofuro[3,2-c]pyrazolo[1,5-a]pyridines as melatonin receptor (MT1/MT2) ligands.
    Koike T; Takai T; Hoashi Y; Nakayama M; Kosugi Y; Nakashima M; Yoshikubo S; Hirai K; Uchikawa O
    J Med Chem; 2011 Jun; 54(12):4207-18. PubMed ID: 21568291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Melatonin, selective and non-selective MT1/MT2 receptors agonists: differential effects on the 24-h vigilance states.
    Ochoa-Sanchez R; Comai S; Spadoni G; Bedini A; Tarzia G; Gobbi G
    Neurosci Lett; 2014 Feb; 561():156-61. PubMed ID: 24406151
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tricyclic alkylamides as melatonin receptor ligands with antagonist or inverse agonist activity.
    Lucini V; Pannacci M; Scaglione F; Fraschini F; Rivara S; Mor M; Bordi F; Plazzi PV; Spadoni G; Bedini A; Piersanti G; Diamantini G; Tarzia G
    J Med Chem; 2004 Aug; 47(17):4202-12. PubMed ID: 15293992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and pharmacological evaluation of pentacyclic 6a,7-dihydrodiindole and 2,3-dihydrodiindole derivatives as novel melatoninergic ligands.
    Attia MI; Witt-Enderby PA; Julius J
    Bioorg Med Chem; 2008 Aug; 16(16):7654-61. PubMed ID: 18657980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alternative Radioligands for Investigating the Molecular Pharmacology of Melatonin Receptors.
    Legros C; Brasseur C; Delagrange P; Ducrot P; Nosjean O; Boutin JA
    J Pharmacol Exp Ther; 2016 Mar; 356(3):681-92. PubMed ID: 26759496
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anxiolytic effects of the melatonin MT(2) receptor partial agonist UCM765: comparison with melatonin and diazepam.
    Ochoa-Sanchez R; Rainer Q; Comai S; Spadoni G; Bedini A; Rivara S; Fraschini F; Mor M; Tarzia G; Gobbi G
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Dec; 39(2):318-25. PubMed ID: 22789661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of structure-activity relationships for MT2 selective antagonists by melatonin MT1 and MT2 receptor models.
    Rivara S; Lorenzi S; Mor M; Plazzi PV; Spadoni G; Bedini A; Tarzia G
    J Med Chem; 2005 Jun; 48(12):4049-60. PubMed ID: 15943478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of substituted N-[3-(3-methoxylphenyl)propyl] amides as MT(2)-selective melatonin agonists: improving metabolic stability.
    Hu Y; Zhu J; Chan KH; Wong YH
    Bioorg Med Chem; 2013 Jan; 21(2):547-52. PubMed ID: 23228808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and synthesis of N-(3,3-diphenylpropenyl)alkanamides as a novel class of high-affinity MT2-selective melatonin receptor ligands.
    Bedini A; Spadoni G; Gatti G; Lucarini S; Tarzia G; Rivara S; Lorenzi S; Lodola A; Mor M; Lucini V; Pannacci M; Scaglione F
    J Med Chem; 2006 Dec; 49(25):7393-403. PubMed ID: 17149869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design and synthesis of 4-arylpiperidinyl amide and N-arylpiperdin-3-yl-cyclopropane carboxamide derivatives as novel melatonin receptor ligands.
    Li G; Zhou H; Jiang Y; Keim H; Topiol SW; Poda SB; Ren Y; Chandrasena G; Doller D
    Bioorg Med Chem Lett; 2011 Feb; 21(4):1236-42. PubMed ID: 21237644
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Isoindol-1-one analogues of 4-(2'-methoxyphenyl)-1-[2'-[N-(2"-pyridyl)-p-iodobenzamido]ethyl]pipera zine (p-MPPI) as 5-HT1A receptor ligands.
    Zhuang ZP; Kung MP; Mu M; Kung HF
    J Med Chem; 1998 Jan; 41(2):157-66. PubMed ID: 9457239
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective.
    Liu J; Clough SJ; Hutchinson AJ; Adamah-Biassi EB; Popovska-Gorevski M; Dubocovich ML
    Annu Rev Pharmacol Toxicol; 2016; 56():361-83. PubMed ID: 26514204
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New melatonin (MT1/MT2) ligands: design and synthesis of (8,9-dihydro-7H-furo[3,2-f]chromen-1-yl) derivatives.
    Landagaray E; Ettaoussi M; Leclerc V; Traoré B; Perez V; Nosjean O; Boutin JA; Caignard DH; Delagrange P; Berthelot P; Yous S
    Bioorg Med Chem; 2014 Feb; 22(3):986-96. PubMed ID: 24417958
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of the Mel1c melatoninergic receptor in platypus (Ornithorhynchus anatinus).
    Gautier C; Guenin SP; Riest-Fery I; Perry TJ; Legros C; Nosjean O; Simonneaux V; Grützner F; Boutin JA
    PLoS One; 2018; 13(3):e0191904. PubMed ID: 29529033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.